Follow Us GraphicFacebook IconTwitter IconLinkedIn Icon
Search Graphic

Expert Financial Analysis and Reporting

Gilead's Offer for Pharmasset Follows Closely on the Heels of Roche's Bid for Anadys: Could Achillion and Inhibitex Be Next?

Gilead (GILD) is certainly paying up for Pharmasset with its offer to buy the company at $137 per share ($11…
Read more…

The Bull and Bear Case for Anadys (ANDS, $1.00)

The investment thesis for Anadys is almost totally based on the prospects for its lead drug, ANA 598, which is…
Read more…

Thoughts on Recent Poor Stock Performance (ANDS, $1.09)

Meeting With CEO Steve Worland

Anadys' CEO Steve Worland was in town for the Piper Jaffrey conference along with Investor Relations…
Read more…

Investment Negatives and Positives (ANDS, $2.06)

I had a telephone conversation with CEO Steve Worland to discuss the negatives and positives for Anadys over the next…
Read more…

Initial Meeting with Anadys' CEO Steve Worland (ANDS, $2.33)

I met with CEO Steve Worland and IR contact Amy Conrad at their offices in San Diego. This was my…
Read more…

Update on Anadys' Lead Drug, ANA-598 for Hepatitis C (ANDS, $2.06)

I had a phone conversation with CEO Steve Worland in which he gave me an update on the companyís lead…
Read more…

Onsite Meeting with Anadys' CEO Steve Worland (ANDS, $1.77)

I met with Anadysí CEO Steve Worland and IR contact Amy Conrad at their offices in San Diego for an…
Read more…